HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 11:46:48 2024-06-10 am EDT | ||
| 6.98 EUR | +1.45% |
|
| Current month | +6.17% | ||
| 1 month | +7.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 6.98 | +1.45% |
| 24-06-07 | 6.88 | -0.58% |
| 24-06-06 | 6.92 | +0.87% |
| 24-06-05 | 6.86 | +1.93% |
| 24-06-04 | 6.73 | +1.36% |
Real-time BOERSE MUENCHEN
Last update June 10, 2024 at 11:46 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXZ |
| ISIN | DE000HR5TXZ9 |
| Date issued | 2021-02-25 |
| Strike | 6,705 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.98 € |
|---|---|
| Lowest since issue | 0.93 € |
| Spread | 0.03 € |
| Spread % | 0.43% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat
